询 单
请 填 写 相 关 信 息
产品信息
产品名称
别名
CAS号
结构式 上传
联系方式
公司
联系人
电话
邮箱
内容
提交
中文版 English
请输入产品名称、CAS式、分子式
(3-Hydroxybenzyl)hydrazine | CAS:637-33-2
(3-Hydroxybenzyl)hydrazine
  • 名称:(3-羟基苄基)肼 | (3-Hydroxybenzyl)hydrazine
  • CAS号:637-33-2
  • 别名:NSD 1015; m-Hydroxybenzylhydrazine; m-Hydroxybenzylhydrazine
  • 分子式:C7H10N2O
  • 分子量:138.17
  • EINESC号:

产品描述

物理化学性质

熔点 114-115 ºC**
密度 1.184±0.06 g/cm3 (20 º

安全数据

没有数据没有数据

SDS

来源 SDS样本
没有数据没有数据
产品合成路线
更多

名称 CAS号
更多
文章
同行评议文献
Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study.Heinrich Schulte-Baukloh et al.Journal of pediatric urology, 8(4), 386-392 (2011-09-13) [Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy].Noritaka Kamimura et al.Hinyokika kiyo. Acta urologica Japonica, 57(2), 71-76 (2011-03-18) New strategies for medical management of overactive bladder in children.Annette Schröder et al.Current opinion in urology, 20(4), 313-317 (2011-04-09) Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.Kate McKeage Clinical drug investigation, 33(1), 71-91 (2013-01-05) Determination of propiverine hydrochloride in human plasma by high performance liquid chromatography-tandem mass spectrometry: application to the pharmacokinetic study of a sustained release formulation.Meihua Huang et al.Arzneimittel-Forschung, 61(9), 494-501 (2011-10-28) Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.Umberto Leone Roberti Maggiore et al.Expert opinion on drug metabolism & toxicology, 8(11), 1387-1408 (2012-08-09) Responsiveness and minimal clinically important change in overactive bladder symptom score.Momokazu Gotoh et al.Urology, 78(4), 768-773 (2011-08-23) Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic)Madersbacher H, et al. World Journal of Urology, 19(5), 324-335 (2001) Effect of distigmine combined with propiverine on bladder activity in rats with spinal cord injury.Kimio Sugaya et al.International journal of urology : official journal of the Japanese Urological Association, 19(5), 480-483 (2012-01-10) Efficacy of propiverine, an anticholinergic agent, in young and old rats.Saori Nishijima et al.Life sciences, 89(13-14), 456-459 (2011-08-09) A new method for evaluating the bitterness of medicines in development using a taste sensor and a disintegration testing apparatus.Tsutomu Harada et al.Chemical & pharmaceutical bulletin, 58(8), 1009-1014 (2010-08-06) The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients.F Donath et al.International journal of clinical pharmacology and therapeutics, 49(6), 353-365 (2011-05-27) [Combination therapy with anticholinergics and alpha-blockers for the treatment of overactive bladder in female patients--pilot study].J Krhut et al.Ceska gynekologie, 74(6), 416-420 (2011-01-21) The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum.Melinda Wuest et al.World journal of urology, 29(2), 149-155 (2011-02-22) A placebo-controlled, multicentre study comparing the tolerability and eYcacy of propiverine and oxybutinin in patients with urgency and urge incontinence.Madersbacher H, et al. BJU International, 84, 646-651 (1999) Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.Momokazu Gotoh et al.International journal of urology : official journal of the Japanese Urological Association, 18(5), 365-373 (2011-02-22) Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms.Hong Sang Moon et al.Urology, 76(2), 509-509 (2010-06-16) Urinary incontinence in children.Daniela Schultz-Lampel et al.Deutsches Arzteblatt international, 108(37), 613-620 (2011-10-07) Editorial comment from Dr Dmochowski to propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.Roger R Dmochowski International journal of urology : official journal of the Japanese Urological Association, 18(5), 374-374 (2011-03-02) Influence of a fat-rich meal on bioavailability of extended-release and immediate-release propiverine.Werner Siegmund et al.Journal of clinical pharmacology, 52(5), 681-690 (2011-05-10) Taste masking of propiverine hydrochloride by conversion to its free base.Tetsuo Ogata et al.Chemical & pharmaceutical bulletin, 60(8), 976-984 (2012-08-07) Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.Yasue Kubota et al.Neurourology and urodynamics, 30(7), 1309-1314 (2011-05-12) Editorial comment from Dr Sekido to propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.Noritoshi Sekido International journal of urology : official journal of the Japanese Urological Association, 18(5), 373-374 (2011-03-09) Excitatory effect of propiverine hydrochloride on urethral activity in rats.Katsumi Kadekawa et al.International journal of urology : official journal of the Japanese Urological Association, 19(6), 575-582 (2012-03-02) An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity.A D Asimakopoulos et al.Urologia internationalis, 89(3), 259-269 (2012-07-11) Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study.Matthias Oelke et al.World journal of urology, 29(2), 217-223 (2011-02-18)
备注

Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).

名称 CAS号

相关产品

相关资讯

热门标签
询 单
请 填 写 相 关 信 息
产品信息
产品名称
别名
CAS号
结构式 上传
联系方式
公司
联系人
电话
邮箱
内容
提交